News

Number of news items returned: 81 to 100 records of 411

"Time to replace that bucket" says Trustee Tailored Super

10 June 2017

(8312 views)

  "Time to replace that bucket" says Trustee Tailored Super   "We continue to highlight, that without Smart Defaults like TTS, in 2050 ...

The Tech Corner: BioCube

31 May 2017

(9403 views)

  "The Tech Corner: BioCube A shipping container that processes waste and plant materials into green energy that can run engines and ...

Tractile shades Tesla

25 May 2017

(10386 views)

  "Tractile leaves Tesla solar roof tiles in the shade   Renowned global entrepreneur Elon Musk’s latest product offering, solar roof tiles, are ...

Tooth Booth, CXi Software, News and Events - Funding Strategies Connect May 2017

19 May 2017

(10106 views)

  Tooth Booth, CXi Software, News and Events - Funding Strategies Connect May 2017 Dear Reader, Welcome back for the May edition of ...

Tooth Booth Westfield North Lakes to open August 2017

18 May 2017

(10107 views)

    "Tooth Booth Westfield North Lakes to open August 2017   Tooth Booth are in final discussions with Westfield North Lakes to open ...

Merger Brings Global Financial Network to Melbourne

05 May 2017

(11125 views)

  Merger Brings Global Financial Network to Melbourne    Fast growing capital markets group BlueMount Capital has welcomed Melbourne-based corporate advisory and investment ...

Myriad, Clients and Associate news - Funding Strategies Connect April 2017

20 April 2017

(12638 views)

Myriad, Clients and Associate news - Funding Strategies Connect April 2017   Dear Readers, Welcome back for another edition of our monthly newsletter, ...

BPC Residential Funds - Fully Subscribed

13 April 2017

(12909 views)

  " WE ARE PLEASED TO ANNOUNCE BOSS PRIVATE CAPITAL RESIDENTIAL FUND NUMBER 1 & 2 ARE BOTH NOW FULLY SUBSCRIBED"    Paul Harragon, Managing Director, ...

BPC: Residential Funds - Fully Subscribed

13 April 2017

(12671 views)

  " WE ARE PLEASED TO ANNOUNCE BOSS PRIVATE CAPITAL RESIDENTIAL FUND NUMBER 1 & 2 ARE BOTH NOW FULLY SUBSCRIBED"   Paul Harragon, Managing ...

Future Asset Management International (FAMI)

11 April 2017

(12685 views)

  "Future Venture Capital Offer (FVCO) Our innovative Future Venture Capital Offer (FVCO) provides a compliant VCLP structure for a wide range ...

"Equity crowdfunding bill passed, but proprietary companies still excluded"

20 March 2017

(15795 views)

"Equity crowdfunding bill passed, but proprietary companies still excluded"   "Retail investors will from September be able to buy up to $10,000 ...

Funds, Introductions and Updates - Funding Strategies Connect March 2017

17 March 2017

(12277 views)

Funds, Introductions and Updates - Funding Strategies Connect March 2017 Dear Readers, It has been a busy first quarter so far with ...

Trac Group roll out of Tractile Solar Roofing gains momentum

16 March 2017

(16069 views)

  "Trac Group roll out of TractileTM Solar Roofing gains momentum   Trac Group's strategy to build a network of distributors continues to ...

QinetiQ Selects RobotEye Thermal System for Their CUAS Product Family

14 March 2017

(13409 views)

  "QinetiQ Selects RobotEye Thermal System for Their CUAS Product Family   As the use of drones proliferates, their level of sophistication increases ...

Smarter MySuper defaults

13 March 2017

(13015 views)

  Smarter MySuper defaults    "Are Super Funds being hypocritical? Telling their members who have made an investment choice and are engaged (circa 20%), ...

Queensland Business Development Fund – Co-Investor Application

10 March 2017

(13170 views)

   Queensland Business Development Fund – Co-Investor Application   "Tailored Superannuation Solutions Ltd (“TSS” or the “Company”) is pleased to confirm, following a ...

Nelson Resources appoints CPS Securities

08 March 2017

(13495 views)

  "Nelson Resources appoints CPS Securities   The Nelson Resources Limited (the Company, ASX: NES) Board is pleased to advise that Nelson Resources ...

Tailored Superannuation Solutions Ltd Exceeds Minimum Subscription

22 February 2017

(13561 views)

  Tailored Superannuation Solutions Ltd Exceeds Minimum Subscription "Tailored Superannuation Solutions Ltd (“TSS” or the “Company”) is pleased to confirm that the ...

Nelson Resources extends closing of its Replacement Prospectus

22 February 2017

(13210 views)

   "Nelson Resources extends closing of its Replacement Prospectus   The Nelson Resources Limited (the Company, ASX: NES) Board is pleased to advise ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625